NervGen Pharma Corp. News Releases

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Wed, 17 Dec 2025 16:19:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has filed a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in...

NervGen Pharma Announces Proposed Amendment to Warrants

Fri, 12 Dec 2025 19:51:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that...

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Mon, 24 Nov 2025 07:05:00 -0500

Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injuryCompleted a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291 as the first pharmacologic treatment for spinal cord injuryCompleted a US$10 million non-brokered private placement to support an anticipated Nasdaq...

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Mon, 24 Nov 2025 07:00:00 -0500

Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placeboParticipant-reported outcomes highlight substantial improvements in bladder control and muscle spasticity compared to placeboStatistically significant reduction of hyperactive reticulospinal signaling in upper and lower limbs (via startle MEP), together with previously reported increases in...

NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Wed, 19 Nov 2025 16:26:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has completed its previously announced non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other...

NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Tue, 18 Nov 2025 16:42:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it is conducting a non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other accredited investors. The...

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

Tue, 26 Aug 2025 07:30:00 -0400

Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gainsOngoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory discussions, including seeking alignment with FDA on potential expedited approval pathways Vancouver, British Columbia--(Newsfile Corp. - August 26,...

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Thu, 21 Aug 2025 07:30:00 -0400

Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury modelsReinforced NVG-291's broad therapeutic potential with new data across three distinct injury modelsVancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative...

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Thu, 17 Jul 2025 07:30:00 -0400

Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial Results Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (SCI) and other nervous system disorders, today announced a leadership transition as the Company enters the next phase of development for its first and...

NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update

Mon, 07 Jul 2025 17:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today provided a quarterly update with respect to the Company's previously announced at-the-market equity program (the "ATM Program") launched on December 19, 2025. The ATM Program allows the Company to issue and...